Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

被引：0
|
作者：
Eric S. Daar [1 ]
Chloe Orkin [2 ]
Paul E. Sax [3 ]
Debbie Hagins [4 ]
Anton Pozniak [5 ]
Kimberly Workowski [6 ]
Cynthia Brinson [7 ]
Juan Manuel Tiraboschi [8 ]
Hui Liu [9 ]
Chris Deaton [10 ]
Cal Cohen [10 ]
Sharline Madera [10 ]
Jason T. Hindman [10 ]
Moti Ramgopal [10 ]
机构：
[1] Lundquist Institute at Harbor-UCLA Medical Center,
[2] Queen Mary University of London,undefined
[3] Brigham and Women’s Hospital,undefined
[4] Coastal CARE Centers,undefined
[5] Chelsea and Westminster Hospital,undefined
[6] London School of Hygiene and Tropical Medicine,undefined
[7] Emory University,undefined
[8] Central Health,undefined
[9] Hospital Universitari de Bellvitge,undefined
[10] Gilead Sciences,undefined
[11] Inc.,undefined
[12] Midway Research Center and Midway Specialty Care Center,undefined
来源：
AIDS Research and Therapy | / 22卷 / 1期
关键词：
Antiretroviral therapy; Bictegravir; Body mass index; Dolutegravir; Glucose; HIV-1; Tenofovir alafenamide;
D O I：
10.1186/s12981-025-00732-w
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir
    Calza, Leonardo
    Borderi, Marco
    Colangeli, Vincenzo
    Miani, Teresa
    Nuti, Bianca
    Bon, Isabella
    Lazzarotto, Tiziana
    Viale, Pierluigi
    AIDS, 2022, 36 (01) : 153 - 155
  • [42] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [43] Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips
    Andreatta, K.
    Chang, S.
    Delaney, M.
    Willkom, M.
    Martin, R.
    Graham, H.
    Martin, H.
    White, K. L.
    HIV MEDICINE, 2021, 22 : 72 - 73
  • [44] Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice
    Hoffmann, Christian
    Schewe, Knud
    Fenske, Stefan
    Buhk, Thomas
    Sabranski, Michael
    Adam, Axel
    Hansen, Stefan
    Stellbrink, Hans-Juergen
    ANTIVIRAL THERAPY, 2020, 25 (02) : 83 - 90
  • [45] Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
    Orkin, Chloe
    DeJesus, Edwin
    Sax, Paul E.
    Arribas, Jose R.
    Gupta, Samir K.
    Martorell, Claudia
    Stephens, Jeffrey L.
    Stellbrink, Hans-Jurgen
    Wohl, David
    Maggiolo, Franco
    Thompson, Melanie A.
    Podzamczer, Daniel
    Hagins, Debbie
    Flamm, Jason A.
    Brinson, Cynthia
    Clarke, Amanda
    Huang, Hailin
    Acosta, Rima
    Brainard, Diana M.
    Collins, Sean E.
    Martin, Hal
    LANCET HIV, 2020, 7 (06): : E389 - E400
  • [46] Comparing Lamivudine plus Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice
    Baldin, Gianmaria
    Ciccullo, Arturo
    Lombardi, Francesca
    D'Angelillo, Anna
    Dusina, Alex
    Emiliozzi, Arianna
    Farinacci, Damiano
    Moschese, Davide
    Picarelli, Chiara
    Borghetti, Alberto
    Di Giambenedetto, Simona
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2021, 37 (06) : 429 - 432
  • [47] Comparative observational study of darunavir/cobicistat/emtricitabine/tenofovir alafenamide versus bictegravir/emtricitabine/tenofovir alafenamide in high-risk non-adherent people living with HIV
    Knobel, H.
    Canepa, C.
    Fernandez-Quiroga, M. J.
    Arrieta, I.
    Canas-Ruano, E.
    Villar, J.
    Guelar, A.
    Marcos, A.
    Guerri, R.
    Gonzalez, A.
    HIV MEDICINE, 2023, 24 : 82 - 83
  • [48] Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens
    Yeoh, Daniel K.
    Campbell, Anita J.
    Bowen, Asha C.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (05) : E215 - E216
  • [49] Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
    Monforte, Antonella d'Arminio
    Tavelli, Alessandro
    Di Biagio, Antonio
    Sarmati, Loredana
    Marchetti, Giulia C.
    Bai, Francesca
    Cingolani, Antonella
    Roldan, Eugenio Quiros
    Mussini, Cristina
    Lichtner, Miriam
    Vergori, Alessandra
    Piconi, Stefania
    Orofino, Giancarlo
    Fusco, Francesco Maria
    Bandera, Alessandra
    Nozza, Silvia
    Castagna, Antonella
    Antinori, Andrea
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (06) : 1279 - 1288
  • [50] Comparing lamivudine plus dolutegravir and bictegravir/emtricitabine/ tenofovir alafenamide in antiretroviral therapynaive HIV-infected patients: preliminary results from clinical practice
    Long, H.
    HIV MEDICINE, 2023, 24 : 105 - 106
12345